Table 1.
MSCs’ use in human clinical trials.
| General Indication | Clinical Indication |
Cell Source |
Injection | Phase | Results (Safety/Efficacy) |
Trial Number | Ref |
|---|---|---|---|---|---|---|---|
|
Autoimmune
disease |
Type 1 Diabetes Rheumatoid Arthritis Systemic Lupus |
Auto BM Allo AT Allo UC Auto BM Allo AT Auto UC Allo UC |
Systemic Systemic Systemic Local Local Systemic Systemic |
N.A N.A N.A 2/3 1/2 1 1/2 |
Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and trend for efficacy Safe and clinical efficacy Safe and clinical efficacy |
NCT01068951 NCT03920397 X NCT01873625 NCT01663116 NCT03171194 NCT01741857 |
[42] [43] [44] [45] [46] [47] [48] |
|
Cardiovascular
disease |
Type 2 Diabetes Myocardial infarction Heart failure Ischemic stroke |
Allo UC Auto BM Auto AT Allo BM Auto BM Auto BM Auto BM Auto BM Allo BM Allo BM Allo BM Allo UC Auto BM |
Systemic Local Local Systemic Local Local Local Local Syst/Local Local Systemic Systemic Systemic |
2 2 N.A 1/2 2 2/3 2/3 1/2 1/2 2 2 1/2 2 |
Safe and clinical efficacy
Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and no efficacy Safe and clinical efficacy Safe and no efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy |
NCT02302599 NCT02384018 NCT03276312 NCT01576328 NCT01759823 NCT01392105 NCT04421274 NCT01076920 NCT00883727 NCT02013674 NCT01436487 NCT01739777 NCT00875654 |
[49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] |
| GvHD | Acute GvHD | Allo BM Allo BM Allo BM |
Systemic Systemic Systemic |
3 3 1 |
Safe and differential efficacy
Safe and clinical efficacy Safe and clinical efficacy |
NCT00366145 NCT02336230 X |
[62] [63] [64] |
|
Intestinal bowel
disease |
Crohn’s disease | Allo BM Allo AT |
Local Local |
1/2 3 |
Safe and clinical efficacy
Safe and clinical remission |
NCT01144962 NCT01541579 |
[65] [66] |
|
Organ
transplantation |
Kidney transplantation | Auto BM Auto BM |
Systemic Systemic |
1/2 N/A |
Safe and clinical efficacy
Safe and clinical efficacy |
NCT00734396 NCT00658073 |
[67] [68] |
| Neuro-degenerative disease | Amyotrophic lateral sclerosis Multiple sclerosis |
Auto BM Auto BM Auto BM Auto BM Allo UC Auto NP Auto BM Auto BM Auto BM Auto BM |
Systemic Syst/Local Syst/Local Systemic Systemic Local Syst/Local Systemic Systemic Syst/Local |
1/2 1 1/2 1 1/2 1 1/2 1/2 2 2 |
Safe and clinical efficacy
Safe and clinical efficacy Safe and clinical efficacy Safe and unknown efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and clinical efficacy Safe and trend for efficacy Safe and clinical efficacy |
NCT04821479 NCT01759797 NCT04823000 NCT00813969 NCT02034188 NCT01933802 NCT00781872 NCT01745783 NCT10228266 NCT02166021 |
[69] [70] [71] [72] [73] [74] [75] [76] [77] [78] |
| Viral infection | SARS-CoV-2 | Allo AT Allo X Allo BM |
Systemic Systemic Systemic |
1 1 1/2 |
Safe and clinical efficacy
Safe and no efficacy Safe and clinical efficacy |
NCT04276987 NCT04535856 NCT05019287 |
[79] [80] [81] |
Abbreviations: bone marrow (BM); adipose tissue (AT); umbilical cord (UC); NP, neural progen-itors (NP); allogeneic (allo); autologous (auto); not available (NA).